Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...

A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...

Copenhagen, Denmark Wednesday, July 23, 2025, 10:00 Hrs [IST] ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...